B-type natriuretic peptide testing on risk stratification and short-term prognosis evaluation in patients with first acute myocardial infarction

Objective To explore the relationship between infarction area,major adverse cardiac events(MACE) in hospital and follow-up for 3 months with plama B-type natriuretic peptide(BNP) levels in patients with first acute myocardial infarction(AMI).To assess the value of BNP on risk stratification and prognosis in patients with AMI.Methods 82 AMI patients without heart failure(HF) were enrolled in the study.They were divided into ST elevated myocardial infarction(STEMI) group and non-ST elevated myocardial infarction(NSTEMI) group according to ECG manifestations.By comparison in BNP levels,the patients were divided into three groups,BNP100 ng/L group,BNP≥100-200 ng/L group and BNP≥200 ng/L group.Comparison was made on the incidences of MACE.Results The plasma BNP concentrations in patients with STEMI were significantly higher than those in NSTEMI,(208.4±180.2) ng/L vs(93.6±76.8) ng/L(P0.01).The incidences of MACE were increased with the higher plasma BNP(3.12% for BNP 100 ng/L,8.33% for BNP 100-200 ng/L,46.2% for BNP ≥200 ng/L,P0.01).Conclusion In AMI patients without heart failure,the higher the plasma BNP,the more infarction area,and the more MACE while in hospital and short-term after AMI.BNP testing is valuable in risk stratification and prognosis in patients with AMI.